logo
logo

Tcrcure Nets Over $47M In Funding

Feb 16, 2022•over 3 years ago

Amount Raised

$47 Million

Description

Next-generation cancer immunotherapies developer TCRCure Biopharma has received over 300 million yuan ($47 million) in a new round of funding.

Company Information

Company

Tcr Cure

About

With headcount spanning over150 professionals, TCRCure develops novel cancer immunotherapies that benefit patients who suffer from tumour progression, and chronic diseases, among others. TCRCure, which currently operates in Los Angeles, North Carolina, Chongqing and Guangzhou, claims to launch an initial public offering (IPO) in 2023.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech